Rubio, Jose M. http://orcid.org/0000-0002-0056-4135
Guinart, Daniel http://orcid.org/0000-0001-5078-6716
Kane, John M. http://orcid.org/0000-0002-2628-9442
Correll, Christoph U. http://orcid.org/0000-0002-7254-5646
Funding for this research was provided by:
National Institute of Mental Health (K23MH127300)
Article History
Accepted: 2 May 2023
First Online: 1 June 2023
Declarations
:
: Jose M. Rubio was supported in part by grant number K23MH127300. No funding was specifically received for this article.
: CUC conceptualized the study; DG and JMR conducted the record search; and JMR conducted the analyses and wrote the first iteration of the manuscript. All co-authors provided meaningful edits to the final version of the manuscript. All authors agree to be accountable for this work.
: Jose M. Rubio has been a consultant for Lundbeck, Teva and Janssen, has received research funding from Alkermes, and receives royalties from UpToDate. Daniel Guinart has been a consultant for and/or has received speaker honoraria from Otsuka America Pharmaceuticals, Janssen Pharmaceuticals, Lundbeck and Teva. Christoph U. Correll has been a consultant and/or advisor to, or has received honoraria from, AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris; provided expert testimony for Janssen and Otsuka; served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva; received grant support from Janssen and Takeda; received royalties from UpToDate; and is a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. John M. Kane has been a consultant for or received honoraria from Alkermes, Forum, Allergan, Genentech, Lundbeck, Intracellular Therapies, Janssen Pharmaceutica, Johnson & Johnson, Merck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda and Teva; has received grant support from Otsuka Lundbeck and Janssen; and is a shareholder in Vanguard Research, LB PharmaGroup, and LB Pharmaceuticals, Inc.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.